Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23043941 | 1.00 | GAA (0.65) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL13403293 | 0.87 | HTT (0.56) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL11908439 | 0.81 | KEAP1 (0.59) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL3559010 | 0.81 | MAPT (0.51) | GAAMEN1KMT2AHTTKDM4E | |
| SCHEMBL3435118 | 0.80 | KEAP1 (0.58) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL20756486 | 0.80 | HTT (0.55) | GAAMEN1KMT2AHTTKDM4E | |
| SCHEMBL4598726 | 0.80 | NCF1 (0.56) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL23368536 | 0.80 | KEAP1 (0.53) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL29978474 | 0.80 | KDM4E (0.70) | GAAMEN1KMT2AUSP2HTT | |
| SCHEMBL23043583 | 0.80 | KDM4E (0.70) | GAAMEN1KMT2AUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | claimed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| US-20220315548-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2022-10-06 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315548-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | MCOLN1, MCOLN2, MCOLN3 | GAA 154/4885MEN1 336/4885KMT2A 3579/4885 |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | GAA 445/4885MEN1 3065/4885KMT2A 3246/4885 |
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | GAA 4492/4885MEN1 1293/4885KMT2A 990/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | GAA 4304/4885MEN1 1033/4885KMT2A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.